Literature DB >> 25075013

Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.

Shigeo Koido1, Yutaka Enomoto2, Vasso Apostolopoulos3, Jianlin Gong4.   

Abstract

BACKGROUND/AIM: Vaccination with fusions of dendritic cells (DCs) and mucin-1 (MUC1)-positive tumor cells (FC/MUC1) induces MUC1-specific antitumor immunity. However, little is known about the function of Cluster of Differentiation (CD)4 T-cells primed with FC/MUC1 in MUC1 transgenic (MUC1.Tg) mice.
MATERIALS AND METHODS: CD4 T-cells primed with FC/MUC1 were analyzed by flow cytometry. Antitumor immunity by adoptive transfer of primed CD4 T-cells in Rag2(-/-) mice was assessed.
RESULTS: The effector and memory T-cells generated with FC/MUC1 were crucial to maintenance of long-term antitumor immunity. MUC1-8-mer peptide SAPDTRPA presented by FC/MUC1 was recognized by CD4 and CD8 T-cells. A subset of primed CD4 T-cells possessed cytotoxicity to lyse major histocompatibility complex (MHC) class I and MUC1 positive tumor cells. Interestingly, adoptive transfer of primed CD4 T-cells prevented lung metastasis in Rag2(-/-) mice.
CONCLUSION: CD4 T-cells primed by FC/MUC1 play direct role in antitumor immunity. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CD4 T-cell; MUC1; cancer vaccine; dendritic cell; epitope; fusion cell

Mesh:

Substances:

Year:  2014        PMID: 25075013

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Kazuki Takakura; Jianlin Gong; Haruo Sugiyama; Toshifumi Ohkusa; Hisao Tajiri
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

2.  In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism.

Authors:  Teodora Mocan; Cristian Matea; Flaviu Tabaran; Cornel Iancu; Remus Orasan; Lucian Mocan
Journal:  J Cancer       Date:  2015-05-15       Impact factor: 4.207

3.  MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Authors:  Vani Lakshminarayanan; Nitin T Supekar; Jie Wei; Dustin B McCurry; Amylou C Dueck; Heidi E Kosiorek; Priyanka P Trivedi; Judy M Bradley; Cathy S Madsen; Latha B Pathangey; Dominique B Hoelzinger; Margreet A Wolfert; Geert-Jan Boons; Peter A Cohen; Sandra J Gendler
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

Review 4.  Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Authors:  Liu Yang; Geng Guo; Xiao-yuan Niu; Jing Liu
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

Review 5.  Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.

Authors:  Shigeo Koido
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 6.  Dendritic Cell Therapies for Hematologic Malignancies.

Authors:  Matthew Weinstock; Jacalyn Rosenblatt; David Avigan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

7.  The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer.

Authors:  Vanessa Barriga; Nyanbol Kuol; Kulmira Nurgali; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2019-08-19       Impact factor: 6.575

Review 8.  Tumor Hybrid Cells: Nature and Biological Significance.

Authors:  Maria S Tretyakova; Ayalur R Subbalakshmi; Maxim E Menyailo; Mohit Kumar Jolly; Evgeny V Denisov
Journal:  Front Cell Dev Biol       Date:  2022-02-15

9.  Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.

Authors:  J A Atzin-Méndez; J S López-González; R Báez; M C Arenas-Del Angel; L F Montaño; D Silva-Adaya; R Lascurain; P Gorocica
Journal:  Oncol Rep       Date:  2015-10-13       Impact factor: 3.906

Review 10.  Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.

Authors:  Alexey V Baldin; Lyudmila V Savvateeva; Alexandr V Bazhin; Andrey A Zamyatnin
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.